Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2026 07:45 ET | Source: Ocugen

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22%...
March 23, 2026 07:02 ET | Source: Ocugen

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
November 17, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight

New York, USA, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape |...
December 11, 2024 09:07 ET | Source: Amarna Therapeutics

Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease

Grasse, France and Leiden, the Netherlands – 11 December 2024 – Phenocell SAS (part of Axol Bioscience) a leading provider of stem cell-derived models and services, and Amarna Therapeutics, a...
October 31, 2024 09:00 ET | Source: e-therapeutics plc

e-therapeutics Announces Business Updates and Interim Results

LONDON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced business...
October 17, 2024 08:56 ET | Source: SNS Insider pvt ltd

Dry Age-Related Macular Degeneration Market to Reach USD 10.57 Billion by 2032 with 9.1% CAGR – SNS Insider

Pune, Oct. 17, 2024 (GLOBE NEWSWIRE) -- SNS Insider reports that the Dry Age-related Macular Degeneration Market, valued at USD 4.83 billion in 2023, is expected to reach USD 10.57 billion by the...
December 13, 2023 07:30 ET | Source: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
December 01, 2022 07:30 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting...
April 25, 2022 16:01 ET | Source: Cognition Therapeutics, Inc.

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
February 10, 2022 13:00 ET | Source: DelveInsight Business Research LLP

Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry Age-Related Macular...